meeting will be posted on the Exxon Valdez Oil Spill Trustee Council Web site at www.evostc.state.ak.us. All Exxon Valdez Oil Spill Public Advisory Committee meetings are open to the public.

Kathleen Bartholomew, Acting Director, Office of Environmental Policy and Compliance.

[FR Doc. 2015–13855 Filed 6–5–15; 8:45 am]
BILLING CODE 4334–63–P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—Heterogeneous System Architecture Foundation

Notice is hereby given that, on May 18, 2015, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. ("the Act"), Heterogeneous System Architecture Foundation ("HSA Foundation") has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Oracle, Redwood Shores, CA, has withdrawn as a party to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and HSA Foundation intends to file additional written notifications disclosing all changes in membership.

On August 31, 2012, HSA Foundation filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to section 6(b) of the Act on April 22, 2015 (80 FR 22551).

Patricia A. Brink, Director of Civil Enforcement, Antitrust Division.

[FR Doc. 2015–13909 Filed 6–5–15; 8:45 am]
BILLING CODE P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances Application: MALLINCKRODT, LLC; Correction

The Drug Enforcement Administration (DEA) published a document in the Federal Register of January 28, 2015, concerning a notice of application for registration as a bulk manufacturer of four basic classes of controlled substances. The document inadvertently omitted two basic classes of controlled substances.

Correction

In the Federal Register of January 28, 2015, in FR Doc. 2015–01576 (80 FR 4592), on page 4592, in the second column, in the table of the second paragraph of the Supplementary Information caption, add entries for “Oripavine” and “Tapentadol” to read as follows: